# Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]

> **NCT02170207** · — · COMPLETED · sponsor: **Takeda** · enrollment: 63 (actual)

## Conditions studied

- Acute Stress Ulcer and Acute Gastric Mucosal Lesions

## Interventions

- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT02170207
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2016-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02170207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02170207, "Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02170207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*